MLV-derived vectors have been used with success to achieve sustained correction of two forms of severe combined immunodeficiency (SCID)—SCID-X1 (Gamma-c deficiency) [2] and adenosine deaminase deficiency [3]. Here, ADA is linked to severe combined immunodeficiency.